Editorial: Biomarkers in precision medicine for mental illnesses
Bradley S. Peterson
Precision medicine and biomarker development have become the prevailing paradigm for mental health research. Despite its conceptual elegance and dominance as a research framework, precision medicine has a very limited track record of demonstrable success thus far for mental illnesses, due in varying degrees to the complexity of both the brain and the pathophysiology of mental illnesses, which limits our ability to develop, replicate, and validate biomarkers for use in enhancing clinical care for mental illnesses, especially in high‐risk and complex clinical populations. Research and funding priorities should integrate biomarker development and precision medicine interventions that target the robust behavioral, environmental, and social determinants that we know are important for population‐based mental health.
We hope you enjoy the full editorial of this Issue, which is free on the Wiley Online Library.
Professor Bradley Peterson, Director, Institute for the Developing Mind, The University of Southern California and Children’s Hospital Los Angeles; Director of the Division of Child and Adolescent Psychiatry, Keck School of Medicine, USC; Professor of Pediatrics, Keck School of Medicine of USC; joint editor of JCPP.